• Aucun résultat trouvé

[PDF] Top 20 Characterization of Human Colon Organoids From Inflammatory Bowel Disease Patients

Has 10000 "Characterization of Human Colon Organoids From Inflammatory Bowel Disease Patients" found on our website. Below are the top 20 most common "Characterization of Human Colon Organoids From Inflammatory Bowel Disease Patients".

Characterization of Human Colon Organoids From Inflammatory Bowel Disease Patients

Characterization of Human Colon Organoids From Inflammatory Bowel Disease Patients

... Canada Inflammatory Bowel Diseases (IBD) are chronic inflammatory disorders, where epithelial defects drive, at least in part, some of the ...reconstituted human intestinal epithelial ... Voir le document complet

14

CD4CD8aa Lymphocytes, A Novel Human Regulatory T Cell Subset Induced by Colonic Bacteria and Deficient in Patients with Inflammatory Bowel Disease

CD4CD8aa Lymphocytes, A Novel Human Regulatory T Cell Subset Induced by Colonic Bacteria and Deficient in Patients with Inflammatory Bowel Disease

... subsets of double positive CD4CD8 T cells have been described in the blood of patients and healthy donors among which CD4CD8ab lymphocytes expressing high levels of CD4, CD8a and CD8b, and ... Voir le document complet

17

Ecological Structuring of Temperate Bacteriophages in the Inflammatory Bowel Disease-Affected Gut

Ecological Structuring of Temperate Bacteriophages in the Inflammatory Bowel Disease-Affected Gut

... aim of this study was to elucidate the ecological structure of the human gut temperate bacteriophage community and its role in inflammatory bowel disease ...proportion of ... Voir le document complet

16

IL-7 pathway controls human T cell homing to the gut and culminates in inflammatory bowel disease mucosa

IL-7 pathway controls human T cell homing to the gut and culminates in inflammatory bowel disease mucosa

... controls human effector, but not regulatory T lymphocyte α4/β7 integrin expression II- Anti-IL-7Ra delays colon inflammation in GVHD humanized mice model III- Anti-IL-7Ra prevents acute colitis in humanized ... Voir le document complet

2

[Immunopathogenesis of inflammatory bowel disease.]

[Immunopathogenesis of inflammatory bowel disease.]

... Les MICI sont des maladies très invalidantes en raison de la fatigue associée aux symptômes inflammatoires et à l’état de douleur chronique dans lequel se trouvent les patients. Les MICI affectent la qualité mais ... Voir le document complet

13

Tailoring Biologic or Immunomodulator Treatment Withdrawal in Inflammatory Bowel Disease.

Tailoring Biologic or Immunomodulator Treatment Withdrawal in Inflammatory Bowel Disease.

... Department of Gastroenterology, University and CHU Liège, Liège, Belgium There is currently no cure for inflammatory bowel ...subset of patients. These patients and their doctors ... Voir le document complet

6

Management of patients with inflammatory bowel disease and spondyloarthritis

Management of patients with inflammatory bowel disease and spondyloarthritis

... in Inflammatory Bowel Disease) consensus defined mucosal healing in combination with resolution of symptoms as one of the major treatment goals for patients with IBD 41 ...rates ... Voir le document complet

46

Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy

Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy

... stages of malignancies), and that patients were not only exposed to anti-TNF agents but also to immunomodulator and anticancer therapies, and the follow-up duration was ...risk of incident cancer. No ... Voir le document complet

8

Intestinal dysbiosis in Inflammatory Bowel Disease associated with primary  immunodeficiency.

Intestinal dysbiosis in Inflammatory Bowel Disease associated with primary immunodeficiency.

... NCT02909244). Patients with IBD in remission were recruited at the Gastroenterology Department of the Saint Antoine Hospital (Paris, France) and provided informed consent (local ethics committee: Comité de ... Voir le document complet

26

Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines

Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines

... pp65) of colon tissue, or detection of CMV DNA in colonic tissue by quantitative PCR; no evidence for extra-intestinal organ damage (lung, retina); no elevation of blood liver tests of ... Voir le document complet

33

The laminin response in inflammatory Bowel disease: protection or malignancy?

The laminin response in inflammatory Bowel disease: protection or malignancy?

... grading of colitis was performed on the Swiss-roll comprising the entire colon and ...assessment of the inflammatory degree was ...concentrations of pro-inflammatory cytokines ... Voir le document complet

13

View of Inflammatory Bowel Disease: An interview with Dr. John Marshall

View of Inflammatory Bowel Disease: An interview with Dr. John Marshall

... in Inflammatory Bowel Disease? What direction would you like to see Canada take with regards to management of this chronic disease? I think there is lots of research still to be ... Voir le document complet

4

Association mapping of inflammatory bowel disease loci to single variant resolution.

Association mapping of inflammatory bowel disease loci to single variant resolution.

... (3.3% of the total size of these credible sets, Supplementary Table ...catalogue of variants with minor allele frequency (MAF) > 1% in European populations, we believe our current fine-mapping ... Voir le document complet

19

Strategic use of immunosuppressants and anti-TNF in inflammatory bowel disease.

Strategic use of immunosuppressants and anti-TNF in inflammatory bowel disease.

... pharmacokinetics of the anti-TNF and decreased the formation of anti-drug antibodies that may lead to allergic reaction and treat- ment failure [26, 27] ...superiority of anti-TNF therapy ... Voir le document complet

6

Evidence for non-neutralizing autoantibodies against IL-10 signalling components in patients with inflammatory bowel disease.

Evidence for non-neutralizing autoantibodies against IL-10 signalling components in patients with inflammatory bowel disease.

... Antibodies of the IgG isotype Sera of 20 healthy donors as well as 52 IBD patients were subjected to ELISA testing in search of anti-IL- 10 IgG ...out of 52 IBD patients (15%) ... Voir le document complet

7

Comprehensive molecular characterization of human colon and rectal cancer

Comprehensive molecular characterization of human colon and rectal cancer

... coverage of ,3–4-fold and a corresponding physical coverage of ...regions of two genes in putative fusion events, of which 18 were predicted to code for in-frame events (Supplementary Table ... Voir le document complet

9

Ocular symptoms are not predictive of ophthalmologic inflammation in inflammatory bowel disease

Ocular symptoms are not predictive of ophthalmologic inflammation in inflammatory bowel disease

... rate of ocular inflammation in our large cohort of IBD ...era of biologics, a large part of our patients were treated with immunomodulators and/or anti-TNF agents ...prevalence ... Voir le document complet

49

Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy.

Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy.

... status, disease duration, IBD phenotype according to Montreal classification, type and dosage of the anti-TNF agent, concomitant medication, and disease activity (based on physician's appreciation) ... Voir le document complet

11

Discrimination between inflammatory bowel disease (IBD) phenotypes by GC×GC-HRTOFMS

Discrimination between inflammatory bowel disease (IBD) phenotypes by GC×GC-HRTOFMS

... DISCRIMINATION BETWEEN INFLAMMATORY BOWEL DISEASE (IBD) PHENOTYPES BY GC×GC-HRTOFMS Nicolas J. Di Giovanni 1 , M-A Meuwis 2 , E Louis 2 , J-F Focant 1 1 MS Laboratory Organic and Biological ... Voir le document complet

1

CD8+CD28- regulatory T lymphocytes prevent experimental inflammatory bowel disease in mice.

CD8+CD28- regulatory T lymphocytes prevent experimental inflammatory bowel disease in mice.

... piece of the distal colon was removed and fixed in 10% buffered ...mucosal inflammatory cell infiltrates with or without minimal epithelial ...diffuse inflammatory cell infiltrates, sometimes ... Voir le document complet

43

Show all 10000 documents...